Program
pegvaliase
Also written as “Pegvaliase”, “rAvPAL-PEG” and “BMN165 20mg/day”.
Its studies are mostly in Phenylketonurias, led by BioMarin Pharmaceutical.
Furthest: phase 4, since Mar 13, 202610 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioMarin Pharmaceutical | 102 open or running | phase 4since Mar 13, 2026 | Mar 6, 2008 | Sep 30, 2027phase 4 · NCT07477691 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2008First study: phase 1 study in PhenylketonuriasFirst studyNCT00634660 · 25 enrolled · United States
- Jun 17, 20092 phase 2 studies in PhenylketonuriasNCT00925054, NCT00924703
- Sep 29, 2010Phase 2 study in PhenylketonuriasNCT01212744 · 16 enrolled · United States
- Mar 5, 2012Phase 2 study in PhenylketonuriasNCT01560286 · 24 enrolled · United States
- Mar 18, 2013Phase 3 study in PhenylketonuriasNCT01819727 · 261 enrolled · United States
- Jun 18, 2013Phase 3 study in PhenylketonuriasNCT01889862 · 215 enrolled · United States
- Sep 4, 2018Phase 3 study in PhenylketonuriasNCT03694353 · 37 enrolled · United States
- Feb 1, 2022Phase 3 study in PhenylketonuriasNCT05270837 · 55 enrolled · United States, Germany
- Mar 13, 2026Phase 4 study in PhenylketonuriasNCT07477691 · 12 planned · United States
Ahead
- Sep 30, 2027Primary completion: phase 4 study in PhenylketonuriasNCT07477691
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07477691Phenylketonurias · United States | 4 | Recruiting | Sep 30, 2027 | 12 |
| NCT05270837Phenylketonurias · United States, Germany | 3 | Active, not recruiting | Jan 14, 2025 | 55 |
| NCT03694353Phenylketonurias · United States | 3 | Completed | Jan 13, 2021 | 37 |
| NCT01889862Phenylketonurias · United States | 3 | Completed | Jan 13, 2016 | 215 |
| NCT01819727Phenylketonurias · United States | 3 | Completed | Nov 25, 2015 | 261 |
| NCT01560286Phenylketonurias · United States | 2 | Completed | Sep 2013 | 24 |
| NCT01212744Phenylketonurias · United States | 2 | Completed | Apr 2015 | 16 |
| NCT00924703Phenylketonurias · United States | 2 | Completed | Jan 31, 2019 | 68 |
| NCT00925054Phenylketonurias · United States | 2 | Completed | Jun 2015 | 40 |
| NCT00634660Phenylketonurias · United States | 1 | Completed | Apr 2009 | 25 |
How it is read
Names in the registry
- “Pegvaliase”, 3 entries
- “rAvPAL-PEG”, 3 entries
- “BMN165 20mg/day”, 1 entry
- “BMN165 40mg/day”, 1 entry
- “BMN 165 (rAvPAL-PEG)”, 1 entry
Conditions, from the studies’ own filings
- Phenylketonurias, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.